title: Reversible neurotoxicity of interleukin-2 and tumor necrosis factor: correlation of SPECT with neuropsychological testing.
abstract: A 41-year-old man developed subacute neurotoxicity associated with interleukin-2 and tumor necrosis factor therapy for metastatic renal cell carcinoma. Cognitive deficits revealed on neuropsychological testing and frontal lobe perfusion deficits revealed on SPECT resolved after 1 month. Findings suggest possible neuroanatomic and physiologic substrates of cytokine neurotoxicity.
authors.affiliation: Department of Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
authors.forename: C A
authors.initials: CA
authors.lastname: Meyers
authors.forename: A D
authors.initials: AD
authors.lastname: Valentine
authors.forename: F C
authors.initials: FC
authors.lastname: Wong
authors.forename: N E
authors.initials: NE
authors.lastname: Leeds
mesh_terms: D000328:Adult; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D007031:Hypothalamus / Q000000981:diagnostic imaging* / Q000187:drug effects*; D007376:Interleukin-2 / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D009483:Neuropsychological Tests; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D016207:Cytokines; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha